Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

NCT06772623 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06772623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06772623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 6, 2025
Completion date
November 30, 2027
Enrollment
252 (estimated)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

c-met, non small cell lung carcinoma